|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/48 | |
| A61K 31/517 | |||
| A61P 35/00 | |||
| A61P 35/02 |
| (11) | Number of the document | 3340969 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16762933.6 |
| Date of filing the European patent application | 2016-08-26 | |
| (97) | Date of publication of the European application | 2018-07-04 |
| (45) | Date of publication and mention of the grant of the patent | 2021-02-17 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/048905 |
| Date | 2016-08-26 |
| (87) | Number | WO 2017/035443 |
| Date | 2017-03-02 |
| (30) | Number | Date | Country code |
| 201562210923 P | 2015-08-27 | US |
| (72) |
WALTERS, Colin, US
BOWEN, William, US
SUN, Yali, US
BRUMFIELD, Jay, US
SHEN, Xiaoxuan, US
ZOU, Daozhong, US
GHOSH, Indrajit, US
|
| (73) |
Celgene Corporation,
86 Morris Avenue, Summit, NJ 07901,
US
|
| (54) | PHARMACEUTICAL COMPOSITIONS COMPRISING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE |
| PHARMACEUTICAL COMPOSITIONS COMPRISING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE |